Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

Glendon E. French, III net worth and biography

Glendon French, III Biography and Net Worth

CEO of Pulmonx

Glendon E. French has served as our President, Chief Executive Officer and as a member of our board of directors since December 2014. From January 2014 to November 2014, Mr. French served as Chief Executive Officer and as a director of ApniCure, a medical device company. From October 2010 to December 2012, Mr. French served as President, Pulmonary Endoscopy for Boston Scientific Corporation, a medical device company. From December 2003 to October 2010, Mr. French served as President and Chief Executive Officer and as a director of Asthmatx, Inc., a medical device company. Mr. French serves as the Executive Chairman of the board of directors of Levita Magnetics International Corp., a medical device company. Mr. French holds a B.A. in History from Dartmouth College and an M.B.A. from the Wharton School at the University of Pennsylvania. We believe that Mr. French is qualified to serve as a member of our board of directors because of his extensive leadership experience and knowledge of the medical device industry.

What is Glendon E. French, III's net worth?: The estimated net worth of Glendon E. French, III is at least $8.40 million as of March 1st, 2024. Mr. French, III owns 1,116,758 shares of Pulmonx stock worth more than $8,398,020 as of April 24th. This net worth approximation does not reflect any other investments that Mr. French, III may own. Learn More about Glendon E. French, III's net worth.
How do I contact Glendon E. French, III?: The corporate mailing address for Mr. French, III and other Pulmonx executives is , , . Pulmonx can also be reached via phone at 1-650-364-0400 and via email at [email protected]. Learn More on Glendon E. French, III's contact information.
Has Glendon E. French, III been buying or selling shares of Pulmonx?: Glendon E. French, III has not been actively trading shares of Pulmonx during the last ninety days. Most recently, Glendon E. French III sold 6,954 shares of the business's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $9.06, for a transaction totalling $63,003.24. Following the completion of the sale, the chief executive officer now directly owns 1,116,758 shares of the company's stock, valued at $10,117,827.48. Learn More on Glendon E. French, III's trading history.
Who are Pulmonx's active insiders?: Pulmonx's insider roster includes Daniel Florin (Director), Glendon French, III (CEO), David Lehman (General Counsel), Geoffrey Rose (Insider), and Derrick Sung (CFO). Learn More on Pulmonx's active insiders.
Are insiders buying or selling shares of Pulmonx?: In the last twelve months, insiders at the sold shares 29 times. They sold a total of 138,984 shares worth more than $1,628,116.18. The most recent insider tranaction occured on March, 22nd when insider Geoffrey Beran Rose sold 1,184 shares worth more than $11,082.24. Insiders at Pulmonx own 5.7% of the company. Learn More about insider trades at Pulmonx.
Information on this page was last updated on 3/22/2024.

Glendon E. French, III Insider Trading History at Pulmonx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/1/2024	Sell	6,954	$9.06	$63,003.24	1,116,758
2/15/2024	Sell	20,000	$14.60	$292,000.00	1,121,344
1/18/2024	Sell	10,000	$12.77	$127,700.00	1,141,344
12/21/2023	Sell	10,000	$12.42	$124,200.00	1,151,344
12/1/2023	Sell	6,676	$10.34	$69,029.84	1,161,344
9/1/2023	Sell	6,527	$10.01	$65,335.27	1,168,020
7/20/2023	Sell	15,000	$12.68	$190,200.00	1,174,547
6/15/2023	Sell	10,000	$12.68	$126,800.00	1,189,547
6/1/2023	Sell	6,533	$11.48	$74,998.84	1,199,547
3/1/2023	Sell	2,895	$11.03	$31,931.85	1,032,580
12/1/2022	Sell	3,631	$5.93	$21,531.83	1,034,313
9/15/2022	Sell	25,000	$20.00	$500,000.00	1,027,944
8/18/2022	Sell	50,000	$20.59	$1,029,500.00	1,055,884
6/1/2022	Sell	2,523	$18.05	$45,540.15	1,104,994
3/1/2022	Sell	1,132	$25.91	$29,330.12
2/17/2022	Sell	12,500	$27.22	$340,250.00
1/20/2022	Sell	12,500	$25.98	$324,750.00
12/16/2021	Sell	25,000	$31.05	$776,250.00
12/1/2021	Sell	1,421	$32.73	$46,509.33
11/18/2021	Sell	25,000	$35.98	$899,500.00
10/21/2021	Sell	25,000	$39.75	$993,750.00
9/20/2021	Sell	23,571	$37.36	$880,612.56
9/16/2021	Sell	25,000	$38.86	$971,500.00	1,155,370
9/1/2021	Sell	1,421	$40.09	$56,967.89
8/19/2021	Sell	25,000	$36.63	$915,750.00
7/15/2021	Sell	25,000	$38.73	$968,250.00
6/17/2021	Sell	25,000	$42.96	$1,074,000.00	1,252,359
5/20/2021	Sell	25,000	$41.95	$1,048,750.00	1,219,825
4/15/2021	Sell	25,000	$43.75	$1,093,750.00	1,229,895

Glendon E. French, III Buying and Selling Activity at Pulmonx

Pulmonx Company Overview

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Today's Range

Now: $7.52

$7.43

$7.67

50 Day Range

MA: $9.49

$7.40

$14.65

2 Week Range

Now: $7.52

$7.21

$14.84

Volume

198,804 shs

Average Volume

504,284 shs

Market Capitalization

$289.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

From Banyan Hill Publishing | Ad

See how you can invest alongside him